ARTICLE | Clinical News
Exalgo regulatory update
February 22, 2010 8:00 AM UTC
Covidien said FDA extended the PDUFA date for an NDA for Exalgo hydromorphone to manage moderate to severe pain in opioid-tolerant patients to March 1 from Feb. 22. Covidien has U.S. commercialization...